OMEICOS Therapeutics GmbH
- Address
- Robert-Roessle-Strasse 10, Buch
Sponsor Overview
Specializations
Primary Mitochondrial Disease
OMEICOS Therapeutics GmbH’s clinical research is centered on primary mitochondrial disease, with attention to patients affected by myopathy and cardiomyopathy alongside inflammation. The sponsor’s trial activity reflects interest in conditions linked to impaired mitochondrial function and multi-system involvement.
- Myopathy
- Cardiomyopathy
- Inflammation
Research in this area includes evaluation of clinical responses associated with changes in GDF-15, a biomarker relevant to mitochondrial disease activity and treatment effect.
Cardiac and Skeletal Muscle Involvement
The sponsor’s studies also focus on the muscular and cardiac manifestations of mitochondrial disorders, covering both skeletal muscle dysfunction and heart muscle disease. These areas are important in understanding the clinical burden of mitochondrial pathology.
- Skeletal muscle dysfunction
- Heart muscle disease
- Multisystem mitochondrial involvement
This therapeutic interest aligns with patient populations experiencing combined neuromuscular and cardiovascular features.
Inflammatory Biomarkers
OMEICOS Therapeutics GmbH has a clear research interest in inflammatory biomarkers associated with mitochondrial disease, particularly markers used to track biological response during treatment. The emphasis on biomarker assessment highlights a focus on measurable disease-related changes.
- GDF-15
- Biomarker response
- Disease activity monitoring
These topics support investigation of how mitochondrial disorders may be tracked through molecular and clinical indicators.
Safety and Tolerability in Rare Disease Care
The sponsor’s research portfolio includes attention to safety and tolerability in the treatment of rare mitochondrial disorders. This area is especially relevant in patient groups with chronic, progressive disease and complex organ involvement.
- Safety
- Tolerability
- Rare disease management
The clinical focus remains on treatment considerations for individuals living with inherited mitochondrial pathology.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 2a Study on Safety, Tolerability, and Pharmacodynamics of OMT-28 in Patients with Primary Mitochondrial Disease-Associated Myopathy/Cardiomyopathy |  Germany Italy The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 8 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial165 other sponsors
Partnered Research Centres
8 centres- Address
- Via Consolare Valeria N 1, 98124 Messina
- Address
- Via Altura 3, 40139 Bologna
- Address
- Via Giacomo Venezian 1, 20133 Milan
- Address
- Ziemssenstrasse 1, Ludwigsvorstadt-Isarvorstadt, 80336 Munich
- Address
- Ernst-Grube-Strasse 40, Kroellwitz, 06120 Halle
- Address
- Venusberg-Campus 1, Venusberg, 53127 Bonn
Want to get in touch with this sponsor?
Send a question and we'll pass it on to OMEICOS Therapeutics GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.